0.2625
1.35%
0.0035
Handel nachbörslich:
.26
-0.0025
-0.95%
Schlusskurs vom Vortag:
$0.259
Offen:
$0.2601
24-Stunden-Volumen:
51,840
Relative Volume:
0.30
Marktkapitalisierung:
$2.60M
Einnahmen:
$6.98M
Nettoeinkommen (Verlust:
$-12.70M
KGV:
-0.0247
EPS:
-10.64
Netto-Cashflow:
$-6.94M
1W Leistung:
-13.85%
1M Leistung:
-17.97%
6M Leistung:
-55.20%
1J Leistung:
-79.49%
Petros Pharmaceuticals Inc Stock (PTPI) Company Profile
Firmenname
Petros Pharmaceuticals Inc
Sektor
Telefon
973-242-0005
Adresse
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK
Vergleichen Sie PTPI mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
PTPI | 0.2625 | 2.60M | 6.98M | -12.70M | -6.94M | -10.64 |
ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Petros Pharmaceuticals Inc Aktie (PTPI) Neueste Nachrichten
Petros Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Petros Pharmaceuticals stock hits 52-week low at $0.28 - Investing.com India
Petros Pharmaceuticals stock hits 52-week low at $0.28 By Investing.com - Investing.com Canada
It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year - Simply Wall St
Short Interest in Zions Bancorporation N.A. – 6.9 (NASDAQ:ZIONL) Increases By 170.0% - Defense World
Petros Pharmaceuticals Amends President’s Employment Terms - Yahoo Finance
Petros Pharmaceuticals adjusts executive's salary and terms - Investing.com India
Petros Pharmaceuticals adjusts executive's salary and terms By Investing.com - Investing.com South Africa
Petros Pharmaceuticals amends preferred stock terms - Investing.com India
Petros Pharmaceuticals amends preferred stock terms By Investing.com - Investing.com UK
Petros Pharmaceuticals sees two board members resign By Investing.com - Investing.com Australia
Petros Pharmaceuticals sees two board members resign - Investing.com India
Board Reshuffle at Petros Pharmaceuticals Following Resignations - TipRanks
Petros Pharmaceuticals, Inc. Announces Board Resignations - Marketscreener.com
Otsuka and Lundbeck Announce Barbara Corcoran Led Campaign to Raise Awareness of Alzheimer’s Dementia - Pharmaceutical Executive
Petros Pharmaceuticals sets date for 2024 annual meeting - Investing.com
Petros Pharmaceuticals reports high comprehension in drug app study - Investing.com
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) - AccessWire
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - AccessWire
A History of Outperforming Analyst Forecasts and Beating the Odds: Petros Pharmaceuticals Inc (PTPI) - SETE News
Analytical Overview: Petros Pharmaceuticals Inc (PTPI)’s Ratios Tell a Financial Story - The Dwinnex
A stock that deserves closer examination: Petros Pharmaceuticals Inc (PTPI) - US Post News
Petros Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 - MSN
Petros Pharmaceuticals (NASDAQ:PTPI) Stock Price Down 10.4% - Defense World
Petros Pharmaceuticals stock hits 52-week low at $0.37 - Investing.com
Joel Baglole - InvestorPlace
Closing Figures: Petros Pharmaceuticals Inc (PTPI)’s Negative Finish at 0.41, Down -3.55 - The Dwinnex
Petros Pharmaceuticals reports promising Web App study - Investing.com
PTPI’s Market Whiplash: -70.74% YTD Decline, -7.41% Plunge in 30 Days - The InvestChronicle
Petros Pharmaceuticals Inc (NASDAQ:PTPI) stock: Is this a flash in the pan today? - US Post News
Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) - AccessWire
Petros Pharma (NASDAQ:PTPI) Stock Quotes, Forecast and News Summary - Benzinga
Get in on Petros Pharmaceuticals Inc’s (PTPI) buy-in window today! - SETE News
Financial Metrics Exploration: Understanding Petros Pharmaceuticals Inc (PTPI) Through Ratios - The Dwinnex
Petros reports successful study for STENDRA OTC switch By Investing.com - Investing.com Canada
Petros Pharmaceuticals Inc Inc. (PTPI) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Petros reports successful study for STENDRA OTC switch - Investing.com
Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance - AccessWire
Quarterly Metrics: Quick and Current Ratios for Petros Pharmaceuticals Inc (PTPI) – DWinneX - The Dwinnex
Can you still get a good price for Petros Pharmaceuticals Inc (PTPI) Shares at this point? - US Post News
Pioneering change: male contraceptives and the coming OTC revolution - Interesting Engineering
The future of health: male contraceptives and OTC innovation - Interesting Engineering
PTPI’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Erectile Dysfunction Drugs Market Size to Hit USD 6.26 Bn By 2033 - Precedence Research
Petros Pharmaceuticals Inc (PTPI)'s Market Momentum: Closing Strong at 0.41, Down -2.50 – DWinneX - The Dwinnex
Petros Pharmaceuticals Inc (PTPI) did well last session? – US Post News - US Post News
Finanzdaten der Petros Pharmaceuticals Inc-Aktie (PTPI)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):